You are here:Home
»
Growth Factors, Cytokines
»
Growth Factors-VEGF
»
Vascular Endothelial Growth Factor-121, Recombinant, Human (VEGF-121)
Vascular Endothelial Growth Factor-121, Recombinant, Human (VEGF-121)
Pricing
For pricing information, USA customers sign in. Outside USA? Please contact your distributor for pricing. Specifications
| Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1 , FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. | | | Catalog # | V2110-04S | | Description | Recombinant Human VEGF-121 produced in insect cells is a double, non-glycosylated, polypeptide chain containing 121 amino acids and having a molecular mass of 28423 Dalton. VEGF121 circulates more freely than other VEGF forms, which bind more tightly with vascular heparin sulfates. Recombinant Human VEGF-121 is purified by proprietary chromatographic techniques. | | Dimers and Aggregates | Less than 1% as determined by silver-stained SDS-PAGE gel analysis. | | Biological Activity | Recombinant Human VEGF-121 is fully biologically active when compared to standards. Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 0.2-0.4 ng/ml, corresponding to a Specific Activity of 5 x 105 IU/mg. | | Endotoxin | 0.1ng/ug (IEU/ug) of VEGF 121. | | Protein Content | Protein quantitation was carried out by two independent methods: | | 1. UV spectroscopy at 280 nm. | | 2. Analysis by RP-HPLC, using a calibrated solution of VEGF-121 as a Reference Standard. | | Solubility | It is recommended to reconstitute the lyophilized Human VEGF-121 in sterile 18M -cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. | | Stability | Lyophilized Recombinant VEGF-121 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution VEGF-121 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. | | Molecular Weight | 28.42kD | | Source | Sf9 insect cells | | Purity | 90% as determined by: | | (a) Analysis by RP-HPLC. | | (b) Anion-exchange FPLC. | | (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel. | | Concentration | ~1mg/ml | | Form | Supplied as a lyophilized powder without additives. | | | Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
External Links
|
